May 10 (Reuters) - Syros Pharmaceuticals Inc:
* SYROS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES
* Q1 REVENUE VIEW $4 MILLION -- THOMSON REUTERS I/B/E/S
* Q1 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S
* SYROS PHARMACEUTICALS - PLAN TO OPEN SINGLE-AGENT, COMBINATION EXPANSION COHORTS IN PHASE 1 TRIAL OF SY-1365 IN MID-2018
* SYROS - EXPECT TO REPORT INITIAL DATA FROM COMBINATION ARMS OF PHASE 2 TRIAL OF SY-1425, DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF SY-1365 IN Q4 2018
* SYROS PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $121.7 MILLION, VERSUS $72.0 MILLION ON DEC 31, 2017
* SYROS - BELIEVES EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSES INTO 2020 Source text for Eikon: Further company coverage:
